Compagnie Lombard Odier SCmA’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$120K	–	673
2021 Q2	$120K	Sell	10,000 -848,429	-99%	-$9.61M	﹤0.01%	393
2021 Q1	$10.8M	Buy	858,429 +848,429	+8,484%	+$11.4M	0.24%	78
2020 Q4	$156K	Hold	10,000	–	–	﹤0.01%	349
2020 Q3	$94K	Hold	10,000	–	–	﹤0.01%	338
2020 Q2	$90K	Hold	10,000	–	–	﹤0.01%	333
2020 Q1	$64K	Hold	10,000	–	–	﹤0.01%	337
2019 Q4	$84K	Hold	10,000	–	–	﹤0.01%	327
2019 Q3	$91K	Hold	10,000	–	–	﹤0.01%	316
2019 Q2	$108K	Hold	10,000	–	–	﹤0.01%	296
2019 Q1	$95K	Hold	10,000	–	–	﹤0.01%	353
2018 Q4	$115K	Hold	10,000	–	–	﹤0.01%	315
2018 Q3	$169K	Hold	10,000	–	–	0.01%	309
2018 Q2	$142K	Buy	+10,000	New	+$166K	0.01%	323

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Compagnie Lombard Odier SCmA's SGMO Position: Q3 2021 in Review

Compagnie Lombard Odier SCmA sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2021, closing a stake of 10,000 shares — an estimated $120K sold.

Compagnie Lombard Odier SCmA first reported a position in SGMO in Q2 2018 and held it in 13 quarters. The position peaked at $10.8M in Q1 2021. 193 funds tracked by Wall St. Rank hold SGMO as of Q3 2021.

Compagnie Lombard Odier SCmA reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2021 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 10,000 SANGAMO THERAPEUTICS INC shares in Q3 2021, an estimated $120K.
Compagnie Lombard Odier SCmA first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 13 quarters.
Compagnie Lombard Odier SCmA's SANGAMO THERAPEUTICS INC position peaked at $10.8M in Q1 2021.
193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2021, filed 28 Oct 2021.